Rational design of HIV vaccines and microbicides: Report of the EUROPRISE network annual conference 2010

Sarah Brinckmann, Kelly da Costa, Marit J. van Gils, David Hallengärd, Katja Klein, Luisa Madeira, Lara Mainetti, Paolo Palma, Katharina Raue, David Reinhart, Marc Reudelsterz, Nicolas Ruffin, Janna Seifried, Katrein Schäfer, Enas Sheik-Khalil, Annette Sköld, Hannes Uchtenhagen, Nicolas Vabret, Serena Ziglio, Gabriella ScarlattiRobin Shattock, Britta Wahren, Frances Gotch

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Novel, exciting intervention strategies to prevent infection with HIV have been tested in the past year, and the field is rapidly evolving. EUROPRISE is a network of excellence sponsored by the European Commission and concerned with a wide range of activities including integrated developmental research on HIV vaccines and microbicides from discovery to early clinical trials. A central and timely theme of the network is the development of the unique concept of co-usage of vaccines and microbicides. This review, prepared by the PhD students of the network captures much of the research ongoing between the partners. The network is in its 5th year and involves over 50 institutions from 13 European countries together with 3 industrial partners; GSK, Novartis and Sanofi-Pasteur. EUROPRISE is involved in 31 separate world-wide trials of Vaccines and Microbicides including 6 in African countries (Tanzania, Mozambique, South Africa, Kenya, Malawi, Rwanda), and is directly supporting clinical trials including MABGEL, a gp140-hsp70 conjugate trial and HIVIS, vaccine trials in Europe and Africa.

Original languageEnglish
Article number40
JournalJournal of Translational Medicine
StatePublished - 12 Apr 2011
Externally publishedYes


Dive into the research topics of 'Rational design of HIV vaccines and microbicides: Report of the EUROPRISE network annual conference 2010'. Together they form a unique fingerprint.

Cite this